Clinical Trial Update: A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases. [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating a single inhalation dose of AZD8871 for efficacy, PK, safety, and tolerability in chronic lung disease (COPD).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• AZD8871 (AZD8871)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: COMPLETED | Results posted: 2020-12-17